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BACKGROUND: Consumer preferences are important to inform the efﬁ cient and 
responsive delivery of health-care services; particularly for the chronically ill. Chronic 
Heart Failure Management Programs (CHF-MPs) are effective at reducing morbidity 
and mortality and are arbitrarily applied in different ways and settings. We know very 
little of consumer preferences surrounding the choice between CHF-MPs applied via 
the patient’s home or a specialist hospital clinic. The Discrete Choice Experiment 
(DCE) offers a method to systematically quantify the relative importance of different 
characteristics of a CHF-MP, from the patient’s perspective. OBJECTIVES: To 
describe the development of a DCE to quantify consumer preferences related to CHF-
MPs. METHODS: A series of 12 semi-structured interviews were undertaken with 
patients enrolled in a clinical trial comparing home and clinic based CHF-MPs (the 
WHICH? Study). Interviews explored the characteristics of a CHF-MP which were 
important to patients. These characteristics were then used as a basis for the design 
of the DCE instrument. A fractional factorial blocked design capable of estimating all 
main and one two-way interaction effect was utilized. RESULTS: Key themes identi-
ﬁ ed by interview participants included delivery, communication, education, and nur-
turing. A CHF-MP DCE instrument was developed describing CHF-MPs in terms of 
characteristics including whether the same nurse is seen at each visit, the cost (includ-
ing travel costs) of seeing the nurse, and access to telephone or exercise/education 
support services. The DCE will now be pilot-tested before being used to elicit the 
preferences of approximately 300 patients enrolled in the WHICH? Study. CONCLU-
SIONS: Interviews with CHF patients suggest consumers value aspects of a manage-
ment program beyond those directly related to health outcomes. The DCE designed 
from this process will be capable of quantifying preferences and estimating willingness-
to-pay for the process-based characteristics of a CHF-MP. 
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OBJECTIVES: Patient perception has been shown to affect the success of pharmacist-
managed clinics such as the anticoagulation clinic (ACC). However, such ﬁ ndings are 
yet to be elucidated in Singapore. The primary objective of this study was to assess 
patients’ perceptions and acceptance of pharmacist-managed ACC in the primary care 
settings in Singapore. The secondary objective was to identify factors that may affect 
patient satisfaction and knowledge on warfarin therapy. METHODS: This was a 
cross-sectional, quality assurance, telephone survey conducted from September to 
December 2009. All patients referred to the pharmacists-managed ACC from nine 
primary care institutions for at least one visit were included, and those with hearing 
disability were excluded. The questionnaire was administered mainly in English, 
Chinese or Malay, and consisted of three sections: 1) patient demographics, 2) a 
20-item, ﬁ ve-point likert scale patient satisfaction questions, and 3) a ﬁ ve-item war-
farin knowledge questions. RESULTS: A total of 149 (39.9%) surveys were eligible 
for analysis. Questions categorized into Friendly Explanation and Managing Therapy 
had mean scores of 3.64 ± 0.55 and 3.54 ± 0.60, respectively. Gender, ethnicity, educa-
tion level and age were not associated with patient satisfaction. Age (p = 0.03) and 
education level (p = 0.01) were negatively and positively correlated with warfarin 
knowledge, respectively. CONCLUSIONS: Overall, patients found the ACC pharma-
cists to be friendly and were satisﬁ ed with the management of the service. Patient 
demographics did not associate with patient satisfaction. Age and education level, 
however, showed to affect warfarin knowledge. 
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OBJECTIVES: To investigate the baseline quality of life of Hong Kong cardiac 
patients who had undergone percutaneous coronary intervention (PCI) and the base-
line characteristics of these patients. METHODS: Eligible cardiac patients at the Prince 
of Wales Hospital during March to September 2009 were recruited into study while 
they were hospitalized for PCI. The generic short form 36 health survey (SF 36) and 
MacNew Heart Disease HRQL questionnaire were used to assess the patient’s baseline 
quality of life. Patients’ social and clinical characteristics were also recorded. 
RESULTS: One hundred patients were recruited (male: 81%; mean age: 62.06 
+/−10.14). The highest incidence of PCI occurred in the age group of 50–59s (30%). 
Smoking patients reported with lower mean scores indicating a poorer quality of life. 
The mean scores of the 8 health domains of SF 36 were physical functioning (PF) 
72.70, role physical (RP) 53.25, bodily pain (BP) 61.55, general health (GH) 49.83, 
vitality (VT) 47.85, social functioning (SF) 71.89, role emotional (RE) 72.67 and 
mental health (MH) 68.06. The mean physical component score (PCS) and mean 
mental component score (MCS) were 36.94 and 47.88, respectively. CONCLUSIONS: 
Risk factors including the male gender and advanced age contributed signiﬁ cantly to 
coronary heart disease. The presence of comorbidities, cigarette smoking, and long-
standing CHD requiring elective PCI also contributed toward a poorer quality of life. 
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OBJECTIVES: To exploit whether disease management program (DMap) is cost-
effectiveness, improvement of quality and outcomes in hypertension intervention at 
community level. METHODS: Four districts were selected to conduct a quasi-exper-
imental study in 2006–2007. About 1442 hypertension patients were enrolled to 
management group (962 cases) and control group (480 cases). Patient blood pressure, 
behavior and lifestyles were surveyed at baseline and followed in 6 and 12 months. 
The cost data were collected from community health institution and disease managers 
by questionnaires. RESULTS: The cost per patient was 968.8 Yuan (RMB) ($143) in 
management group and 740.6 Yuan (RMB) ($109) in control group. The incremental 
cost per patient in management group was equal to 19 Yuan (RMB) ($2.8) per patient 
per month. After a 12-month follow-up, the average systolic blood pressure (SBP) was 
declined 7.96 mmHg and the average diastolic blood pressure (DBP), 4.5 mmHg in 
management group. The individual blood pressure before and after intervention 
matched pairs showed that the average SBP and DBP per patient was reduced 
12.95 mmHg and 7.89 mmHg,respectively. The results illustrate the effectiveness of 
controlling SBP and DBP in management group which is much better than that in 
control group (P < 0.01). However, the cost of declining 1mmHg DBP is much higher 
than the cost of declining 1 mmHg SBP. The incremental cost-effectiveness analysis 
(ICEA) showed that incremental cost for declining 1 mmHg SBP and DBP in manage-
ment group is less than that in control group (0.45 Yuan vs. 83 Yuan). CONCLU-
SIONS: DMap can improve the cost-effectiveness and quality of care in community 
hypertension intervention. The characteristics of DMap is to promote patient self-
management on hypertension by using participatory approach. Patients change their 
lifestyles (diet, smoking, physical exercise and compliance of medicines) so as to 
control their blood pressure. Finally, after 1-year best practice, DMap has been scale 
up to all districts in Shanghai since 2009. 
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OBJECTIVES: To assess the impact on the health-care expenditure and prevention of 
hospitalization of cardiovascular disease (CVD) for beneﬁ ciaries of Taiwan’s National 
Health Insurance (NHI) scheme after rosuvastatin (RSV) become available in NHI’s 
beneﬁ t package in May, 2005. METHODS: Using NHI’s claim data of a nationally 
representative random sample (consisting of 1 million of eligible beneﬁ ciaries) from 
2004–2008, we classiﬁ ed patients > = 20 years of age who received other statins before 
and switched to RSV during May 2005 to April 2006 into switch group (N = 1,040). 
Other patients who received statins therapy except RSV before May 2005 and 
throughout 2008 were classiﬁ ed into control group. Using propensity score (PS), we 
selected match group (N = 1,039) from control group (N = 18,432) based on age, 
gender, prior ambulatory care expenditure, and comorbidities related to the probabil-
ity of switching. The date of ﬁ rst claim for prescribing RSV or other statins after May 
2005 was the index date. Cumulative health expenditure after 1, 2, and 3 years from 
index date were compared between switch group and match group. Cox regression 
model controlling for age, sex, and comorbidities was applied to investigate the rela-
tive risk of hospitalization for CVD between two groups. RESULTS: Patients who 
switched to RSV are signiﬁ cantly consumed more ambulatory care resources after 1-, 
2-, and 3-year of switching ($348, $680, and $1050 more, respectively). Before PS 
matching, the relative risk of hospitalization CVD in switch group is signiﬁ cantly 
higher than control group (RR = 1.38, 95% CI = 1.12–1.70). After PS matching, the 
relative risk is still higher than match group (RR = 1.18, 95% CI = 0.881.58), but 
with less signiﬁ cance. CONCLUSIONS: RSV may be more cost-effective in lowering 
low-density lipoprotein cholesterol, but when taking the prevention of CVD hospital-
ization into account, the cost-effectiveness is diminishing. Putting new drugs into 
coverage should be considered more rigorously when cost is higher but beneﬁ t is not 
substantive. 
